Shares of Syneos Health SYNH moved higher by 3.2% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 19.54% year over year to $1.04, which beat the estimate of $0.90.
Revenue of $1,099,000,000 decreased by 6.63% year over year, which missed the estimate of $1,120,000,000.
Outlook
The upcoming fiscal year's revenue expected to be between $4,900,000,000 and $5,100,000,000.
Conference Call Details
Date: Oct 29, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/5gaeoxvd
Recent Stock Performance
52-week high: $74.25
Company's 52-week low was at $30.02
Price action over last quarter: down 13.62%
Company Overview
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.